Characterisation of the biological potential of fracture non-union tissue by Kelly, Michael.
Characterisation of the biological potential of
fracture non-union tissue
Michael Kelly
MD Thesis University of Edinburgh 2012
i
Abstract
Over 1.1million fractures are estimated to occur annually in England and Wales. Up to 10%
of these are likely be complicated by a delay or failure to heal with significant health and
financial implications. Definitions of fracture non-union are not clear and although the
Weber and Cech classification is still the definitive, misinterpretations remain common.
Current treatment is surgical but the morbidity, particularly where autologous bone grafting is
used, can be as high as 30%. Novel approaches are being tried but few of the strategies have
made the translational impact that the laboratory and animal model data suggested.
The work presented here investigates the feasibility of quantifying the biological potential of
non-unions in patients and in a validated, in vivo model.
Hypothesis: there is quantifiable biological potential in fracture non-union tissue that can be
stimulated leading to osseous union by closed percutaneous injection of induction factors.
Tissue from patients with non-infected fracture non-union undergoing treatment was
examined to determine the feasibility ofquantifying gene activity in small samples of non¬
union gap tissue.
Non-union tissue from the animal model of an established non-union was examined to assess
its osteoblastic potential by culture of extracted cells.
Orthobio logical agents that have shown great potential in gap models of non-union (BMP2
delivered in a viral construct (AdBMP2) and the thrombin peptide, TP508) were assessed to
determine their efficacy in a clinically analogous model of fracture non-union.
Quantifiable metabolic activity was found in the small samples of human non-union tissue.
There was potential to correlate this to the histomorphometric architecture of the tissue.
Cells extracted from the gap tissue of a non-union site in the rat model demonstrated
osteoblastic potential in vitro. However, percutaneous injection of the orthobio logical agents
into the non-union site in vivo failed to stimulate healing.
The tissue at the site of a fracture non-union has a quantifiable metabolic activity that may
have great clinical application and research benefits. Tissue from the non-union site of the
animal model did demonstrate osteoblastic capacity but attempts to effect healing using
percutaneously injected orthobiological agents that have previously shown potential, failed.
This may be due to the chronic timepoint chosen to replicate the clinical situation. Further
work is necessary to determine the prognostic potential of the gene assays and to continue to
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Chapter 1: Classification and treatment of fracture non-union
1.1 The implications offracture non-union
Over 1.1million fractures are estimated to occur annually in England and Wales1 and of these
up to 10% are likely to have problems with a delay or failure to heal2. The potential burden to
healthcare is enormous, estimated as almost £14000 for each non-union3. In addition there is
the societal cost in terms of loss of earnings and prolonged incapacity that has never been
quantified. Currently surgical intervention remains the standard but significant morbidity can
occur in up to 30% of cases4. Given this, there continues to be a major drive to develop better
strategies with considerable industry interest3'5"7.
1.2 Definition offracture non-union
Attempts to address the problems of fracture non-union are not new. Hitzrot8 reviewed the
problem in 1926 and unfortunately, there remain many problems, not least the inability to
agree a definition9. Without consistency of definition in the literature quantification of the
problem and stratification of treatments is almost impossible10. Reported rates for non-union
vary from 0-15% for the humerus, 0-12% for the femur11 and from 0-80% in studies reporting
on the different presentations of tibial fractures12, so this task is not straightforward. Fracture
healing is described using a combination of clinical and radiographic findings9. Clinically, the
absence of pain and return of functional ability indicates successful healing.
Radiographically, this is indicated by progression of the ossification process and commonly
the number of cortices that have 'bridging' callus, i.e. new bone crossing the fracture gap.
Bhandari et al'° sent questionnaires to the 577 practising orthopaedic surgeons. They had a
response rate of 77% and found no consensus in the definition of fracture healing, delayed
union (l-8months) or non-union (2-12 months). For the purpose of licensing treatments and
devices, the Food and Drugs Administration in the United States defined this as a minimum
of nine months since fracture with no visible evidence of healing for three months 13. There
are practical problems with this, not least waiting for nine months with young or active
patients before commencing treatment. Frolke et al14 took a more pragmatic approach,
defining fracture non-union as a disturbance of normal fracture healing with the expectation
that no consolidation will be achieved without focused treatment. An alternative view
considers that six rather than 9 months should have elapsed with no clinical or radiological
evidence ofprogression before it is termed a non-union rather than a delayed union. There
does not appear to be any published evidence for 6 months but it is commonly used15.
1.3 Classification offracture non union
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Weber and Cech's morphological system, reported in 197616 is still the most widely used
classification. Other attempts have been made to further classify the clinical picture. McKee
proposed a system in the AO principles text17. It derives from that of Weber and Cech but
excludes their description of the specific characteristics of the atrophic type. Another
example is that proposed by Paley for tibias18 based on the Ilizarov school. Again it appears
to be an adaption of that of Weber and Cech. Megas19 found few classifications in their
review, suggesting the common theme that they were either atrophic or hypertrophic. Thier
description seems to be an simplification of the Weber and Cech work. Interestingly this now
appears to be the accepted standard as demonstrated by Marino and Ziran20. They reproduced
the Weber and Cech diagram depicting types of pseudoarthroses but naming Weber and
Cech's 'horse's hoof and oligotrophic non-unions as oligotrophic and atrophic respectively,
in effect shifting the paradigm without reference or explanation.
The system of Weber and Cech therefore remains the most comprehensive and accurate. It
was derived from a combined experience of approximately 700 cases treated in either St.
Galen, Switzerland or in Prague, Czech. It divided fracture non-union into 'pseudarthroses'
that have the potential to heal and those that do not. These are commonly referred to as
hypertrophic and atrophic non-unions respectively. Weber and Cech quantified the
vascularity of the non-unions (pseudoarthroses) using scintigraphy and equated this to the
biological potential. In their original diagram the legend comments that the oligotrophic
pseudoarthrosis 'is mistakenly included amongst the so-called atrophic pseudarthroses'. This
indeed continues to be the case. Their group of atrophic non-unions ('defect pseudarthroses')
are now referred to as gap defects. Therefore according to their system, most of those
fractures that are now classified as atrophic non-unions retain the potential to heal if,
according to their conclusions, the mechanical environment can be addressed. They went on
to conclude from their experience that the atrophic pseudorthrosis often quoted in the
literature is only rarely inactive in the biological sense. Despite this, that inaccuracy has
persisted and groups continue to recommend tumour-like excision of what would have
21
originally been classified oligotrophic non-unions .
1.4 Factors associated with asepticfracture non-union
This work has focused on aseptic non-unions. Infection is a very ominous factor associated
with impairment of fracture healing. It is a complex process, the treatment ofwhich is
22difficult and protracted .
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There are many clinical factors associated with problematic fracture healing and non-union
(Table 1). Gaston2 reviewed the evidence for these patient factors implicated and found
many of the clinical papers to be based on opinion or retrospective cohort. Much of the
opinion is based on animal work or in vitro studies23"25.























Fracture and treatment characteristics have also been reported as contributing to the risk of
non-union12. Calori et at9 proposed a new scoring system based largely on their experience
that combined the clinical factors with fracture characteristics and treatment strategies as a
means of predicting union. It is comprehensive and although it has been reported as being
accurate in one retrospective series5 , it has not been widely embraced.
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Table 2 Fracture characteristics associated with delayed/non-union (Bhandari51)
Open fracture
Transverse fracture
Post op fracture gap
Bhandari et al51 studied both the clinical factors and the fracture characteristics associated
with delayed and non-union in tibial fractures in 200 patients treated at two university
centres. They found three simple and robust factors predictive of re-operation (i.e. for delayed
or failure to heal). These were open fracture, transverse fracture and post-operative fracture
gap (Table 2).
In many respects these data support the proposal of Weber and Cech in 1976 that the factors
affecting the potential of a fracture to unite are either biological or mechanical. There can be
overlap, for example, a fracture gap that is too large will adversely affect both the mechanics
and the biology of the healing process but in the majority of cases it appears that the
mechanical factors that predominate.
1.5 Diagnosis offracture non-union
The diagnosis of fracture non-union presents a major problem. Bhandari et alw found no
consensus amongst 444 surgeons replying to their questionnaire. A combination of clinical
and plain radiographic findings remain the standard but functional pain can be a feature even
after successful union52"53 and plain radiographs can be difficult to interpret54. Other methods
have been tried such as bending stiffness55"56 and labelled scans57 but none have become part
of clinical practice. Plain radiographs remain the main diagnostic tool and are often combined
with computerised tomography (CT)58 as a means of confirming the diagnosis and planning
treatment. CT has been shown to be very sensitive but it has also been shown to have a low
specificity (62%) when used in isolation, risking unnecessary procedures59. Other modalities
(for example, MRI, SPECT) are less commonly used in long bones60.
Further work-up of a non-union also excludes infection as the treatment of septic and aseptic
non-union is quite different22.
1.6 Treatment ofaseptic fracture non-union
The current, accepted standard for treatment of fracture non-union is autologous bone
grafting with or without additional or revision of the fracture fixation6"7'61. The surgical
intervention will vary depending on the site, the fracture characteristics and the local
13
expertise. The adequacy of the initial and any subsequent fixation determine the need and
techniques available for the further stabilisation5
1.6.1 Autologous bone grafting
This involves harvesting bone from another site in the same patient. The donor bone has been
defined as having three advantageous properties62. It contains cells that survive the transplant
process and are capable of osteogenic activity. It also contains factors that induce these cells
and those locally to differentiate along osteoblastic lines (osteoinduction). Finally, it provides
a scaffold from which and through which bone formation can occur (osteoconduction).
Another advantage to the patient is that it does not have the infection risk associated with
90 •
allograft tissue. Although these techniques date back to Egyptian times questions regarding
indications and timing remain unanswered.
Weber and Cech63 reserved their autologous bone grafting techniques principally for bone
defects, either from the initial trauma or the debridement following infection and this
approach is making a resurgence (personal communication with Professor C. Moran,
Nottingham). They emphasised the importance of the recipient bed for the graft (i.e. that it
was clean and well vascularised) and the need for stable osteosynthesis.
The iliac crest remains the most utilised source of autologous bone graft and harvesting
techniques remain similar to those depicted in the Weber and Cech monograph. These
include morsellised croutons of cancellous bone, cortical or cancellous strips and block grafts
containing structurally useful cortical surfaces and cancellous bone. The reported morbidity
associated with autologous bone grafting, mainly from iliac crest donor sites, suggests that up
to 10% incidence ofmajor (deep infection, further operative intervention required, prolonged
pain not controlled with simple analgesics) and 40% incidence of minor complications
(haematoma, wound irritation, pain controlled on simple analgesics)64. In addition, the cost is
not negligible but often unreported. Figures are difficult to find but it has been estimated to
be as high as £2413.365. It should be noted that this paper, although very comprehensive in its
•21
costing of the procedure, was from a group also proposing 'polytherapy' , an approach that
uses expensive recombinant protein. The paper formed a basis for their justification of this
additional cost.
Alternatives to standard autologous bone grafting techniques have been sought to avoid the
complications associated with iliac crest donor sites but all confer some surgical morbidity
and until recently only limited graft availability. The reamer irrigator aspirator (Synthes, US)
however is a relatively new technique that can produce comparable amounts of graft to the
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iliac crest66. The aspirate is highly osteogenic and osteoinductive and retains osteoconductive
potential67 but although lower, there is still a risk of surgical morbidity remains66. In addition,
it has a consistency of fine sand which can be more difficult to retain at the fracture site than
cancellous bone graft and has no intrinsic mechanically stabilising properties.
1.6.2Allograft
Allograft is an alternative to autograft that is readily available in the required quantity and
confers no additional morbidity to the patient, apart from the almost negligible infective risk
from the transplanted tissues. It can be used in morsellised form to augment a fracture or
simply to fill defects or can be used to confer a structural advantage (for example, strut
grafts). The quality of the graft can vary between specimens and there is an associated cost
that can be from £600 to over £2000. The processing of the bone required to reduce the
infection risk means that the properties of the material are diminished: it remains
osteoconductive but the osteoinductive capacity is diminished and the osteogenic potential is
no longer present.
1.6.3 BMPs andfracture non-union
Attempts have been made to improve the characteristics of allograft bone by augmenting it
with substances to improve its osteoinductive capacity. This involves the addition of a
recombinant protein with osteoinductive properties and bone morphogenetic proteins 2 and 7
(BMP2, BMP7) are now commonly used in clinical practice.
Bone morphogenetic proteins (BMPs) are part of the transforming growth factor p (TGFP)
family and have been shown to have bone inductive properties. The term was first coined by
Marshall Urist in 196768"69. BMPs are unique in that they induce terminal differentiation
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along osteoblastic pathways and also enhance the differentiated osteoblast functions . They
achieve this by binding transmembrane serine/threonine kinase receptors leading to activation
of the mothers against decapentaplegic (SMAD) 1 and 5 pathways71. Their actions are subject
to multiple regulatory steps at the extra- and intracellular level. They are unique among the
osteogenic factors in that they can induce bone formation when injected in isolation into
muscle or subcutaneous pouches. BMP2 and BMP7 recombinant proteins are licensed for
clinical use and have been used to wither in isolation or as an augment to allograft bone with
some success. Jones et al72 compared allograft with recombinant BMP2 to autograft in 30
patients. They found it to be safe and as effective as autograft and it avoided the additional
surgical morbidity. Friedlaender et al6 used BMP 7 in tibial non-unions. They randomised
124 patients to either autograft or BMP7 and found the latter to be as effective but with less
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surgical morbidity. Therefore BMPs appear to have a role but they remain very expensive
(£2063-£3898 per case (local pharmacy figures)) and as yet have not been shown to be
superior to autograft. They have a dose dependent effect that is independent of the host but
require concentrations in excess of one thousand times higher than the body level ofBMPs.
Given their efficacy, several groups recommend their use as a standard in the treatment of
fracture non-unions, particularly those classified as atrophic21'73-74 and suggested that despite
the additional expense they are cost-effective3"65.Garrison in the Cochrane review73
commented that the role ofBMPs in fracture non-union remained unclear and that there was
considerable industry involvement in the available evidence.
1.6.4 Recombinantproteins and gene therapy in fracture non-union
Other proteins that have been trialled but have made less clinical impact than BMP2 and
BMP7. The thrombin peptide, TP50876-81 has been used in clinical trials including
osteoporotic wrist fractures82. Thrombin is a serine protease with a key role in haemostasis.
Activated thrombin becomes bound within the clot it induces then is released slowly with its
breakdown peptides that are themselves also biologically active. Both it and its degradation
peptides promote osteoblastic differentiation and proliferation from mesenchymal progenitor
cells 83 and inhibit apoptosis84. TP508 (Chrysalin®) is a synthetic 23 amino acid, non-
proteolytic peptide representing a binding domain of human thrombin that has been shown to
recruit inflammatory 85, angiogenic and mesenchymal cells and lead to increased collagen III
86 87 • 88 76
production " . TP508 has been shown to stimulate angiogenesis in wounds and promote
migration and proliferation of osteoblast progenitor cells 79. A single injection ofTP508
solution has also been shown to result in increased callus formation in a closed fracture
model 77and to improve ossification in models of distraction osteogenesis76'81'89. The
promotion of angiogenesis combined with mesenchymal cell migration and proliferation
suggested that this peptide also had potential in the treatment of atrophic non union.
Other proteins have shown considerable potential in lab or animal studies (vascular
endothelial growth factor (VEGF), platelet derived growth factors (PDGF)90-95) but have yet
to make to the translational stage.
Expense, dose and delivery systems are additional considerations when using any
recombinant protein. BMP2 and BMP7 are available in powder form or as soaked in a
collagen sponge to slow the elution and prolong the effect. In solution they dissipate quickly
from the site of application and although carrier systems can control elution they introduce
foreign material. It has been used in a collagen carrier in open tibial fractures96. TP508 is
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available in power or microsphere form, the latter having been shown to be more efficacous78'
97 in bone, again because of a more prolonged dissipation.
Viral vectors for gene delivery have been tried as a means of administering bioactive peptides
including BMP2 98. The advantage is that they are much cheaper than recombinant proteins
and can lead to a more sustained release that can be titrated by varying the dose 99 and virus
type100. They involve the insertion of the gene sequence of the protein of choice as a plasmid
into a replication deficient virus that is expanded on specific cell lines that provide the
relevant replication exon. They are then purified for injection into the recipient tissue where
the protein is produced as part of the replication cycle. Adenoviral delivered BMP2 (Ad-
BMP2) has been used successfully in several gap models including rat101. In these models the
viral construct was injected at 5-7 days following the creation of the gap. There have been a
few Phase I clinical trials of gene therapy102. These have used adenovirus and adeno-
associated virus but these vectors have limitations for use in humans because of innate
immunity to the virus. Although relatively safe there are safety concerns and there has been a
reported death from and adenoviral vector, albeit one not used for musculoskeletal purposes
and in a severely immunocompromised host103. More potent constructs such as lentivirus are
available99 but pose greater safety concerns that have so far limited their use and these
concerns have limited the progression of translational work98.
Viral vectors, in addition to being powerful delivery tools have brought interesting insights
into the characteristics of fracture non-union sites. These behave as a 'privileged' system that
is relatively self-contained (i.e. little viral product is found in the surrounding tissues or
systemically) and enjoy a degree of freedom from systemic immunosurveillance (the virus
continues to produce the protein for much longer than would be anticipated in an
immunocompetent host if given systemically)104.
1.6.5 Timing of intervention
Blick and co authors 105 reviewed approaches to bone grafting in tibial fractures in the
introduction to their study. Suggested time had been 6 and 12 weeks base mainly on
individual series106"108 or on texts and reports from meetings (see references Blick paper105).
The rationale was either to alter the natural history of the anticipated delayed or non-union
with grafting at 6 or 12 weeks. In their study, Blick et al reviewed those grafted within 16
weeks of the index procedure. It compared this mixed group of high energy injuries with case
matched historical controls and found that the study group healed an average of 11.7 weeks
sooner. The 16 weeks interval chosen was a reflection ofpractice at the time with delays in
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definitive closure with grafting recommended at least two weeks after this. Current standards
demand closure within the first 72 hours109 and, in addition, fixation techniques have become
much more robust. In their series, Blick"" had most treated in an external fixator followed by
a period in cast. However their attempt to rationalise the use of autologous bone graft to
prevent unnecessary delay of treatment based on definition13 remains but there is still no clear
guidance as to the optimal time to intervene particularly with modern technologies and
practices remain varied. There is little further in terms of comparing times to intervene and
the principles established by Blick et al are still widely quoted. Marino20 concentrated mainly
on the technical aspects of bone grafting and this is likely to be because, with the paucity of
publications, there is little to discuss regarding timing.
BMP2 has been trialled in fractures at high risk of non-union at the initial procedure. BMP2
with reported success initially %. There were confounding factors in this study and when
these were controlled for no advantage was seen"0.
1.6.6 Alternative therapies in the treatment offracture non-union
Alternative therapies that would obviate the need for any surgical intervention thereby
avoiding all the described risks remain an attractive prospect. Attempts at this are not new;
Physick 111 in 1803 treated a humeral non-union by means of a percutaneously passed seton
(silk threaded needle). There are now several techniques licensed for use in clinical practice
but although the industry for these alternatives is estimated as being worth over $1 billion20,
supporting evidence remains incomplete.
Low intensity pulsed ultrasound treatment represents the bulk of the market in non-operative
strategies and in 2006 was worth £350 million in the US alone"2. Busse et al published
systematic review of randomised controlled trials on the use of low intensity ultrasound on
fractures'l2. Only one trial reported specifically on non-union"3 and although they showed a
positive effect it was underpowered. Having reviewed 13 studies, Busse and co-workers
concluded that although use of low intensity ultrasound was common the evidence was only
of low or moderate quality. The better trials found no significantly positive effects. Another
review in one of the main orthopaedic journals concluded that the evidence was
overwhelmingly positive 114 for the use of low intensity ultrasound but did not include
negative studies. The reason for the technique's popularity and it widespread use is probably
best summed up by Jingushi et al115 when they concluded that it "has been shown to be
effective without causing either serious invasiveness or any undue risk". Other modalities
(electrical stimulation, hyperbaric oxygen) have also been tried with varying popularity.
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Again the evidence is at best weak 116"119and large, properly conducted trials are necessary to
demonstrate efficacy.
Further on from these non-operative strategies are those that try to achieve healing, like
Physick, by percutaneous means. These aim to avoid open surgery by injection of growth
factor concentrates directly into the non-union site. Flernigou et al have established a very
interesting body ofwork looking at the mesenchymal capacity ofmarrow in patients with
fracture non-unions120"121. Around this they have developed a technique of aspiration and
concentration of iliac crest marrow using relatively simple methods and injecting this into
non-union sites with reasonable reported success122"123. This in theory places a concentrate of
both growth factors and mesenchymal progenitor cells into the non-union. The technique has
been reproduced in a few cases in other centres [personal communication Vrahas, M,
Massachusetts General Hospital, Boston, US]. There are technical difficulties (appropriate
concentration, harvest of the correct cell lines and injection into a very small, closed space)
and larger series are required. A similar technique, platelet rich plasma injection, has been
commercially marketed for many musculoskeletal indications including fracture non-union.
Again evidence remains preliminary124 .
1.7 Conclusion
Fracture non-union remains an unsolved, significant clinical problem. Consensus on
definitions remains elusive and the longstanding classification appears to be misquoted in
most of the contemporary literature. There remain many unanswered questions with regard to
the nature of the process itself and the tissues involved but because of the heterogeneity of the
patient population and fracture site characteristics clinical studies are difficult. The current
treatments are effective but are associated with considerable morbidity and are expensive.
Many interesting and innovative techniques are emerging but the levels of evidence
supporting them remain inadequate and most appear to add a level of expense. These studies
though continue to evolve the understanding of the processes of fracture healing and the
characteristics of the non-unions.
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Chapter 2: Characterising the gap tissue in human fracture non-union
2.1 Introduction
There are difficulties in definition and classification of fracture non-union. The most utility
definition is that of Fro Ike14 that defined non-union as a point in the fracture healing process
where focused and accurate treatment was required in order to achieve consolidation.
Classifying the non-unions is more difficult. Much ofwhat is currently described as
'atrophic' non-union20 was classified as 'oligotrophic' by Weber and Cech in their original
monograph16. Their scintigraphy studies showed activity that they interpreted as biological
potential. It is similar to the vascular and metabolically activity demonstrated in the work of
Brownlow and Reed 125-127 in an animal model of atrophic non-union. This latter group then
went on to show that vessel density was similar in samples from human hypertrophic and
atrophic non-union tissue and healing fractures. It is not clear that the atrophic tissue was
strictly classified according to the original Weber and Cech work. Mesenchymal cells
128
demonstrating pluripotentiality have been isolated from 'hypertrophic' non-union tissue
further confirming the assumption of biological potential by Weber and Cech and better
defining that potential. Hofmann et al 128 published a very robust cellular and RNA analysis
on cells extracted from the endosteal cancellous bone adjacent to 10 human hypertrophic
non-unions. They compared these to similar samples from patients undergoing implant
removal after uneventful fracture healing and found that the cells from the hypertrophic non¬
unions had reduced viability, differentiation potential and gene expression in culture
compared to those from normal subjects. The implication was that although the cells from the
non-union could demonstrate osteoblastic potential in vitro, their biological capacity in vivo
was limited. Seebach et al 129 followed up the earlier work of Flernigou et al 120-121 showing
that the numbers ofmesenchymal colony forming units (i.e., the osteoblastic potential) was
greatly diminished in bone marrow aspirate from patients with established fracture non¬
unions. They were the first to suggest that non-union had systemic manifestations. These data
suggest a biologically complex environment and underestimation of this may account for the
disappointing translational results 73. There remains the assumption that the gap tissue is at
21best inert or even inhibitory and recommendations are for excision^ . Indeed, in the Hofmann
work this tissue was carefully removed and discarded.
2.2 Aim
The work presented here sampled this non-union gap tissue in patients undergoing
augmentation or revision of the fixation of fracture non-unions and examined the genetic
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profile and cellularity. The primary aim was to determine if it was feasible to profile the gene
activity of the non-union tissue pertinent to fracture healing.
2.3 Hypothesis
The hypothesis was that there would be sufficient cells in sampled non-union tissue to profile
activity in the genes related to fracture healing.
2.4 Materials and Methods
Inclusion Criteria:
Samples were obtained from 5 consecutive patients presenting to Vancouver General
Hospital with a fracture non-union. This number was chosen to accommodate the time
constraints of this feasibility study. The definition of non-union used was that suggested by
Frolke et al14: "a disturbance of normal fracture healing with the expectation that no
consolidation will be achieved without focused and accurate treatment". In addition, the
diagnosis was not made until 6 months had elapsed from the index or previous intervention.
Exclusion criteria were: infection, tissue from known HIV, Hepatitis B or C patients, and
generalized inflammatory conditions.
Samples were taken as part of the standard surgical approach and no additional approaches
were carried out to obtain samples. Local ethical approval was obtained (ethic number: H07-
01921) for the study and all participants gave informed consent separate to that for their
procedure. Three or four samples were taken from each patient. These varied in size
according to the site and the anatomy of the non-union. They ranged between 27-64 mm3
approximately. One or two samples were placed in formalin, fixed in paraffin embedded in
wax and sectioned. The other samples were macerated under sterile conditions using a
scalpel, placed in RNA later then stored at -70°C for mRNA analysis.
mRNA analysis
The samples were thawed to room temperature, further macerated in the RNAlater solution
using two scalpel blades then placed in an eppendorf tube. This was centrifuged at 8000 x G
for lOseconds and the excess RNAlater solution removed with a pipette. 1ml ofTRIzol
reagent (Applied Biosystems) was added to lyse the sample and vortexed until emulsified.
0.2ml of chloroform per millelitre ofTRIzol was then added. The cap was secured and the
solution shaken vigorously for 15 seconds and transferred to a water bath where it was
incubated at 25 °C for 3 minutes. Following this the tube was centrifuged at 12000 x G for 15
minutes, separating the homogenates into the lower red phenoFchloroform base, an interface
and an aqueous upper phase containing the RNA. The upper aqueous phase was removed
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with a pipette taking care not to disturb or inadvertently draw up any of the interphase. The
RNA was then cleaned and retrieved using the RNeasy spin columns (Qiagen). The final
elution was placed into 30pl RNAase free water. The RNA was quantified using the microdot
photospectrometry system. cDNA cloning was carried out using the high Capacity cDNA
Archive kit (Applied Biosystems) using 20pl of 80ng/pl mRNA for each sample. The
standard mix was prepared using 7pl of each sample and again quantified using the microdot
system. The cDNA was then archived at -20 °C.
Probes were obtained from Applied biosciences for the genes listed in figure 2 and the qPCR
carried out using the Taqman Fast Universal kit (Applied Biosystems).
Table 3 Target genes to assess biological activity of non-union tissue
All probes purchased BD Biosciences
(http://www.bdbiosciences.com/services/customtechnologyteam/).
Osteoprotegerin (OPG), Rank Ligang (RankL), Bone Sialoprotein (BSP), Osteocalcin
(OCN), Osteopontin (OPN), Collagen Type I (C0L1), Collagen Type II (C0L2), Collagen
Type III (C0L3), Collagen Type X (COLIO), TNF receptor associated factor 6 (TRAF 6),
Tartrate resistant acid phosphatase (TRAP), Cathepsin K (Cath K), Transcription factor SOX
9 (S0X9), Osterix (OSX), Alkaline Phosphatase (AlkPhos), Adipocyte protein 2 (AP2),
Peroxisome Proliferator-activated Receptor 2 (PPAR2), Peroxisome Proliferator-activated
Receptor Gamma (PGAR).
Marker for Gene Product no. Comments
Osteoclastic
activity




BSP HS00173720_ML Proteins associated with ordered
hydroxyapatite depositionOCN HS00609452 GL
OPN HS00959010_ML
Collagen COLIal HSOO164004_ML Type III collagen associated with repair






COLX al HS00166657 ML





Chondroblasts SOX9 HS00165814-ML Combined with collagen II as marker of
chondroblastic activity
Osteoblasts OSX HS00541729_ML Combined with collagen I as markers of
osteoblastic activityAlk Phos H500758162_ML




The paraffin embedded specimens were sectioned at 5 pm intervals and stained using H&E,
von Kossa, TRAP and Masson Trichrome. Samples were processed courtesy ofMargaret
Luk, Pathology Department Vancouver General Hospital.
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2.5 Results
Samples of non-union tissue were obtained in five patients. There were differences found in
the consistency of the tissue. Some samples were grainy and difficult to macerate with a
scalpel while other samples were soft and fibrous and easily macerated. Two samples from
the one patient had different handling properties. Half of each sample was used for
histological analysis and half for RNA extraction.








Only very small amounts of nucleotide were isolated from the samples. This had been
anticipated in the study design and therefore only a limited number of genes were examined.
The cellularity of each sample was controlled for using thel8s rRNA housekeeping gene and
showed great between samples (Figure 1). The 18s rRNA figure shows the total quantity
isolated in nanograms. This gene has been used in other studies looking at mesenchymal
tissue and shown to be robust130"131. The variations therefore reflect differences in cellularity
between specimens. In addition, two samples from one patient (ANU01 and ANU02)
underwent separated RNA extraction and also showed variation. Figures 2-7 below represent
the mRNA shown as a ratio of the quantity ofmRNA obtained relative to the cellularity of
the specimen (i.e. normalized to the 18s rRNA housekeeping gene so that it is more
representative of the gene activity).
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Figure 1 18s quantities in the non-union samples
Y axis represents the quantity (ng) of 18s RNA extracted from each sample. This was used to
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Figure 2 mRNA expression in all genes examined
Represented as a ratio of gene activity relative to 18s activity to control for differences in
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Figure 3 Osteoblastic activity
The genes that have been reported as to be relevant to bone formation are: were bone

















ANU 01 ANU 01a ANU02 ANU 03 ANU 04 ANU 06
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Figure 4 Osteoclastic activity
The genes examined were osteoprotegerin, rank ligand, TNF receptor associated factor 6,
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Figure 5 Collagen profile
Collagen I is associated with bone, Collagen III with repair or immature tissue while

















Figure 6 Chondroblastic activity
SOX 9 is closely associated with chondrogenic activity. Collagen II is also indicative of this.
■ SOX 9
Figure 7 Non-collagenous proteins
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2.5.2 Histology
Images below are from left to right x25, x200 and x400 magnification respectively. They are
illustrative of the architecture of the non-union tissue. The H&E stain showed areas of bland,
unmineralised and cell sparse matrix separating cellular islets ofwoven bone. The Masson-
Trichome demonstrated the relations of the fibrin/cellular areas (red) to the
collagen/cartilaginous scaffold (blue). Nuclei stain blue/black. It also showed blood vessels
within the cellular areas arrow). The von Kossa stain shows areas of osteoblastic activity
(brown) which appears to correspond to the cellular areas within the relatively acellular
matrix. The TRAP stain showed areas of osteoclastic activity (brown) and proved difficult for
technical with loss of adherence of the sample to the slide in the initial sections. It did show











The images below are illustrative of the clinical picture as the non-unions progressed from
their initial treatment.
X-ray 1 shows one view of a non-union of distal tibia with failure (breakage) of the implant.
It is an apex anterior deformity with rounding off of the bone end suggestive of an 'atrophic'
non-union. Other areas of the site show bone activity more in keeping with a 'hypertrophic'
non-union. It was agreed clinically among three senior orthopaedic surgeons that this would
not heal without intervention. X-ray 2 showed the healed non-union following posterolateral
plating as a staged procedure to rule out infection.
X-ray 1 X-ray 2
X-ray 3 (below) shows a femoral non-union with an intramedullary nail in situ. The patients
activities were greatly limited by ongoing thigh pain and he continued to used a walking aid.
The medial side (left on the x-ray) has the appearance of an 'atrophic' non-union (Marino20)
or an 'oligotrophic' non-union (Weber and Cech16). X-ray 4 (below) showed the healed non¬
union following plating. The patient was fully ambulatory without pain in his thigh.
30
X-ray 3 X-ray 4
2.6 Discussion
This study demonstrated that the there is a measurable gene activity in the gap tissue of
fracture non-unions. The gap tissue was not excised in these patients and by the time the
patient was considered healed clinically, it had ossified. Therefore while other published data
120 121 129 132has suggested a potential that is at best limited ' ' , it appears that the non-union
tissue does retain adaptive capacity and can form bone. This is the clinical experience in the
unit where this work was undertaken and underpins their approach to the management of
fracture non-union. This work is pilot data but it supports the feasibility of relating the
mesenchymal and osteoclastic activity of the non-union tissue to the histomorhometric
architecture and to the clinical behaviour or the adaptive/healing potential of the fracture.
Until now, osteoclast activity in relation to fracture healing and non-union has been largely
ignored133. Much focus has been placed on translational research. This work has examined a
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clinical practice that seemed at odds with the published data " ' ' and examined it at
the cellular level. This novel perspective highlighted a number of points.
Firstly, fracture non-union remains poorly defined9 making understanding the pathology and
rationalizing potential treatments even more difficult. The US Food and Drug
Administration's definition of nine months from index incident is difficult to justify clinically
when continuing pain and failure of return to function pressure earlier intervention. Therefore
the pragmatic definition of Frolke14 was used but it relies on clinical acumen and is therefore
more difficult to standardise for the purposes of research. Classification remains a problem,
most surgeons still divide non-unions into hypertrophic and atrophic varieties considering
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them to be hypervascular and avascular types respectively49. Further, there is discrepancy in
the literature between the original work ofWeber and Cech16 and that which is now classified
as an 'atrophic' non-union20. Recent work that has shown 'atrophic' non-unions (avascular)
to be as vascular as those with hypertrophic morphology (hypervascular)125'127 . However, it
did not define which definition was used. This makes interpretation of their results more
difficult.
Many non unions will therefore demonstrate evidence of both morphologies (e.g. ANU0701).
The Frolke definition14 circumvents the need for this tier of classification in that it establishes
simply that there is a failure of consolidation that requires intervention. Gerstenfeld et al134
suggested that the first step in approaching questions on fracture healing was a quantitative
definition of the spatial geometry of the skeletal tissue morphogenesis during normal healing.
In their animal model they demonstrated that this seemed to occur along the embryonic
growth patterns. This study has not been repeated in human non-union tissue and was beyond
the scope of this study. It might however explain the mixed morphological patterns in bones
like the femora shown in this work.
Clinical studies have been hampered by the heterogeneity of the patient population, their
injury patterns, treatments and clinical courses. This has been a major factor in attempts to
produce reliable animal models where many of these events can be better controlled. These
however can present a different set of problems135. Previous studies have not addressed the
heterogeneity of the non-union tissue itself. Published work has focused mainly on the
consistencies within the material and failed to comment on the heterogeneity. Wen et al 136
commented on the abnormal crystal and colloid structure that was present in all of their
samples. Reed et al 127 also commented only on the similarities. In the work presented here,
the tissue showed diversity in terms of the handling properties and gene profiles. These
characteristics should be documented in future work. Cellularity, as estimated using the 18s
rRNA gene, and gene activities also varied between samples. One similarity was that the
mRNA extraction yielded only very small amounts of nucleotide in all the samples. Thus
there are potentially extrinsic (between non-unions) and intrinsic (within the same non-union
gap tissue) heterogeneities that need to be included in any analysis particularly when
designing translational work.
The histological analysis showed areas that were largely acellular interspersed with cellular
areas where the cell type and appearances suggested woven bone and blood vessels. An
accurate histomorphometric mapping was beyond the remit of this study but the data here
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suggests that this is feasible even with the small samples obtained. The size of the samples
for this work was between 3-4mm in diameter and yielded the sufficient nucleotide for
analysis and tissue for histology. The assumption is that the samples being contiguous are
likely to share similar characteristics in terms of cell content.
The probes were selected to give an indication ofmesenchymal (osteoblastic, chondroblastic
and adipoblastic) and osteoclast activity and for the non-collagenous proteins associated with
hydroxyapatite crystal deposition. It was felt that these probes were sufficient to provide an
accurate, practical picture of cellular activity in the non-union tissue. Techniques, such as
microarray may be useful in future work but the amount of nucleotide available from the
samples may be the limiting factor.
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Lawton at al ' and Hofmann et al have examined the osteoblasts at the bone ends
associated with non-unions. The former group described an altered phenotype 137-138 and the
latter correlated this to reduced proliferative and differentiation potential and decreased
capacity for mineralization. The conclusions were that this was a pathological phenotype. It
was not considered that it may be an adaptive and therefore physiological response. It should
also be noted that in both groups the cells within the non-union tissue itselfwere not
examined. The assumption is that the tissue has no inherent healing potential and in the
Hofmann group132 the gap tissue was carefully removed. This bias contrasts with
observations in this study where the non-union tissue was left and had ossified by the time it
was judged to have healed clinically. This suggests that despite the reported degenerative
199 191 19 Q
nature of the osteoblasts " and the paucity of colony forming units ' in the fracture non¬
union patient, the tissue remains adaptive enough to heal. It is not possible to tell from the
current data whether the cells within the non-union tissue or cells recruited systemically
and/or locally were responsible for the healing.
Collagen III was expressed in all samples very much in keeping with the accommodative
no
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nature of the tissue and with the work ofLawton et al . Interestingly, collagen X was
expressed in two of the samples and appeared to correlate with Sox9 expression, a
chondrocyte marker. Collagen X is a marker of hypertrophic chondrocytes 139"140 and may
suggest senescence of the cartilaginous tissue in the non-union site. There was no evidence of
collagen II expression. Collagen I expression also appeared to be low across most of the
samples suggesting a steady state. Collagen type 1 is known to have a low turnover in normal
bone139 which could account for the low expression in the samples.
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This work has demonstrated the feasibility of quantifying the metabolic activity in small
samples of non-union tissue and the potential to relate this to histological appearance and
clinical behaviour. It showed gene activity suggestive of osteoblastic and osteoclastic
metabolism in the non-union gap tissue and that there was observed heterogeneity between
patients and within different areas of the non-union site. Correlating gene expression to
histology and clinical activity would have major benefits both clinically and with regard to
research.
34
Chapter 3: Model of fracture 'atrophic' non-union
3.1 Introduction
Roach et al in their excellent critique of experimental approaches 133 advocate that the level
of question determines the model. For fracture non-union the level is that of the organism
because the individual constituents appear to behave differently in isolation that when a
composite in vivo. The fracture non-union patient population is very heterogeneous and this
is one of the major problems with assessing clinical interventions. Animal models allow
standardisation of the host and fracture non-union characteristics but present other difficulties
14'. Small animal models are cheaper and quicker but they have greater healing potential and
osseous union is more difficult to prevent 135'142. Higher animals are closer to the human
situation but are expensive and very time consuming to use. Even in large animals the
physiological response to injury can be different to that of humans 143 creating problems
when translating conclusions.
A rat model of an 'atrophic' fracture non -union was used for this study. This is a validated
model that is analogous to the Weber and Cech definition of an 'atrophic' non-union. In
addition, the interventions were carried out on established non-unions rather than in the acute
phase. Again, this is analogous to the clinical scenario and it differs from the majority of
intervention studies published1 ' 4"148. The non-union was created by the introduction of a
gap that was less than half the bone diameter (i.e. non-critical) and stripping of the endosteum
and periosteum to the same distance. No foreign material was introduced. The importance of
this is that it recreates a comparable environment to the injury resulting from high energy
trauma where the risks of non-union are greatest.
As has been stated, there are problems with drawing conclusions for clinical interventions
from animal studies, particularly small animals. The latter tend to overestimate the efficacy of
interventions. Therefore if an intervention is successful in a small animal model it may have
some benefit in the clinical situation and there is a rationale for further research. If however,
it fails to impact in the small animal model and the study design is robust then that particular
strategy is unlikely to have an impact clinically.
3.2 Method
The model used for this project was of an 'atrophic' fracture non-union in a rat described by
Reed et al 149
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Brass 30mm M4 screws
316LVM stainless steel, 0.5 X 35mm, cold drawn wire, bright anneal
Araldite instant clear glue syringe ( Homebase, Product no. 234035)
Construction of ring mounting
A carbonfibre block was milled to provide a pedestal to mount four Ml6 nylon rings for
accurate drilling (courtesy of John Lissimore, Biomedical Engineering, University of
Edinburgh). Each fixator was therefore constructed as a set. A suspension of lubrication oil
and water was used to cool the rings during drilling so that there was no thermal distorsion.
The mould was mounted in the Turret CNC (computer numerical control) Milling machine
and centred. A 4.2mm drillbit was used.
Drilling of holes
The holes were drilled in the nylon ring such that they were off centre. This meant that on
removing a section the gap left could be varied to either wide or narrow. Two rings were cut
leaving a wide gap and used proximally to leave room for the proximal calfmusculature.
Those with the narrow gap were used distally. The holes were drilled using distance from the
centre of the ring calculated along two orthogonal planes. Therefore, the first hole was
11.55mm to the left. The bit then returned to the centre and was moved 10.47mm to right
followed by 4.88mm perpendicular in a distal direction. Once the holes were drilled the
unwanted sections were cut and the all edges chamfered.
Pin preparation
0.5mm pins were made to order by Alloy Wire International using 316LVM (medical grade)
stainless steel. These were therefore of the same construction as K-wire and the fine wires
used in Ilizarov and Taylor-Spatial frames. The wires were blunt on arrival. The point was
created to approximate the 'Medin' design proposed by Piska et al.150 using a fine grinding
















Size 3 scalpel handle
Size 11 scalpel blade
0.8mm burr (round head)











Anaesthetic and Preparation of Operative site
A single intraperitoneal injection of a mixture of Hypnorm® and Hypnovel®, each at 1.15pl
per gram body weight. The leg was then shaved using clippers and cleansed with Betadine
solution.
Insertion of Wires
The bony anatomy of the leg and ankle was palpated. In particular the level of the ankle was
noted. A variable speed foot control drill was used for all pin insertion. The point of entry for
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the first pin was on the lateral border, just superior to the ankle .It was passed at a 20° angle
to the tibia in an anterior-posterior lateral-medial direction. The next wire was passed 3mm
above this but in a posterior-anterior direction, again at approximately 20 0 to the axis of the
tibia. The third distal wire was passed anterior-posterior 4mm above the second. The fourth
was passed posterior-anterior 3mm above the third. The tibia was templated against a dummy
frame and the position of the top wire of the proximal set marked. These were then inserted
as for the distal set but in a proximal to distal order. The external fixator was then attached to
the eight wires as shown in the diagram. Each fixator was constructed to match the wire
placement with care taken to avoid creation of tensile forces as these were attached to the
rings. The wire ends were then covered in rapidly setting resin to secure their position.
Osteotomy
Once the fixator was secured the area of leg between the proximal and distal rings was again
prepared using Betadine. A longitudinal incision was made and extended through the fascia.
A retractor was inserted medially then laterally exposing 6-8mm of tibia. The scalpel blade
was used to excise the periosteum for 2mm on either side of the osteotomy site. Care was
taken to remove the periosteum posteriorly where the sides of the bone meet at a ridge. A
1mm osteotomy was created using the 0.8mm round headed burr. The gap was verified with a
1mm feeler gauge. The ends of the bone were cooled with saline throughout. The endosteum
was stripped on either side by curettage using 23G needles bent at 90° so that the cutting edge
could be used effectively anteriorly with one and posteriorly with the other. The fibula was
fractured using three-point bending and the gap rechecked. The wound was then closed with
4/0 Vicryl rapide and Vetbond.
Following the osteotomy the wires were glued to the position to which they had been secured
on the frame with the rapid setting Araldite resin. The whole construct was then wrapped
with Vetwrap, taking care not to cause constriction on the hamstrings and leaving the wound
area exposed for inspection.
Post-Operative Care
Immediately post-operatively, all animals received 0.25ml Bupenorphine. If there were any
signs of distress this was repeated at twelve-hour intervals. The animals were wrapped, kept
warm and observed until they had recovered from the anaesthetic. An initial weight was also
taken. Thereafter they were checked on a daily basis.
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3.3 Discussion
The rat model used in this work has been published previously and been shown to reliably
produce an 'atrophic' non union reliably l49. In this study there was a 5% rate of union, all of
which occurred in the initial 4 weeks. No animals went on to heal if there had been no signs
of osseous activity on the 4 week radiograph. All had further check radiographs at 8 weeks
prior to any intervention to confirm this.
All animals began weightbearing on the operated limb from the second day post operatively
and continued to use the limbs in a quadripedal gait pattern and in bipedal stance when
exploring their surrounds throughout the experimental interval, again suggesting that the
construct was stable.
Rats would often try to nibble the nylon rings as part of their self hygiene. Initially, several
nibbled through the entire rings and were excluded. The problem was solved by reapplying
the Vetwrap® on the second and third days post operatively after which the animals no
longer ate the frames.
During the creation of the non-union care was taken to prevent thermal necrosis of the bone
ends and all were checked for 'paprika' like bleeding at the end of the procedure. All gaps
were checked with a feeler gauge and likewise for the level to which the endosteum and
periosteum were stripped.
The operative time involved in constructing the fixator and operating on the bone ends as
described was 1.5 hours. Intra operatively in several animals the saphenous vein was avulsed
by the most distal wire. This led to a minor ooze at the time of surgery and some post
operative bruising but there were no untoward effects. The morphology of the proximal tibia
in the rat is triangular and in some this was very narrow necessitating a slight alteration in
wire direction in order to achieve adequate wire purchase.
In one animal the self hygiene led to wound breakdown. This was monitored closely and
healed in 6 days but the animal was excluded as infection could have complicated the non¬
union.
The time point for the intervention was set as 8 weeks in this study design. However, as no
animal, which had a 4 week radiograph that had failed to show any bone activity, went on to
heal, it would have been appropriate to use 4 weeks as an intervention timepoint in future
work saving on time and costs.
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Chapter 4: The osteogenic potential of non-union gap tissue
4.1 Introduction
The non-ossified tissue at the site of a non-union has been considered to be inert at best or an
obstruction to healing and removed in the course of treatment132 . However, more recent data
challenges this view. Wen et al /36examined humeral non-unions using electron microscopy
and x-ray diffraction and showed scattered islands of hydroxyapatite scattered throughout the
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non-union tissue. Brownlow demonstrated metabolic activity within the non-union
material and the same group also showed that once a steady state had been achieved
'atrophic' non-unions had a vascularity comparable to the healing fracture l25'127'149. They
also demonstrated a similar pattern ofvascularity in their in-vivo model, the suggestion being
that hteir model had similar characteristics to human non-union gap tissue. Boyan et al 151
extracted the cells from the gap tissue in a canine model and were able to demonstrate in vitro
' ' ' |28 132 132
pluripotential mesenchymal cell lines. Other groups ' ' have now also shown that
mesenchymal cells with osteogenic potential can be isolated from human 'hypertrophic' non¬
union tissue.
4.2 Hypothesis
The hypothesis was that there were cells present within the gap tissue with osteoblastic
potential.
This was pilot work to determine if mesenchymal cells with osteogenic potential could be
isolated from a validated rat model of an 'atrophic' fracture non-union.
4. 3 Method
The model used was created as described in the previous chapter and validated by Reed et
al149.
4.3.1 Harvest of the Non-union tissue
At the 8 week time-point the animals were euthanized using increasing C02 levels and death
verified by cervical dislocation. The failure of osseous union was confirmed on fluoroscopy.
Under aseptic conditions the soft tissue in the fracture gap was harvested. The leg including
the fixator was prepared using aqueous betadine. The skin was incised using the previous
incision. This exposed the non-union between the bone ends. Blunt dissection was used to
free it from the muscles posteriorly and medially. Sharp dissection was then used to detach
40
the gap tissue from the bone ends. This was placed into Ependorph tubes of sterile Hanks
solution.
4.3.2 Preparation of the Gap Tissue and Celt Culture
The preparation of the tissue for cell culture was carried out using an aseptic technique in a
designated clean air hood. The tissue was washed three times in phosphate buffered saline
(PBS) then placed in a drop of trypsin and morsellised using a sterile No. 15 scapel blade until
a fine consistency was achieved. This solution was pipetted into a T25 culture flask in 3mis
of standard media (DMEM with 10% Fetal Calf Serum (FCS), 1% streptomycin/penicillin
and l%glutamate). This was left for 3 days before the media was removed. The adherent cells
were washed 3 times with PBS then replaced in 3mls of fresh media. Subsequent media
changes were every 2-3days until day 21-28 when the cells had achieved approximately 90%
confluence.
Once the cells were in a confluent monolayer the media was removed and the cells washed 3
times with PBS. 1ml Trypsin was then applied and the cells incubated at 37°C for 10 minutes
until the majority of cells had detached. The cells were then re-suspended in standard media
and split into two T25 flasks. The cells were then cultured for a further 21 days before being
collected and counted. The resultant cells were plated into 24 well plates at a density of
10000 cells per well in 0.5ml media. Once the cells were confluent on in the wells they were
divided into four groups. The control group was cultured in the standard media. All groups
were culture for 21 days with the media changed every 2-3 days. In addition, prior to each
media change the chondrocyte pellets were centrifuged at 150G for 5 minutes.
At the 21 day timepoint the plates were fixed in 4% paraformaldehyde. The chondrocyte
pellets were placed in a drop of 5% PVA and frozen to -80°C.
4.3.3 Osteogenesis
Cells were cultured in an osteogenic media. This comprised: complete standard media with
the addition of 50pmoPL Ascorbic acid, lOmmol/L P-glycerophosphate and O.lpmoPL
Dexamethasone.
Osteoblastic activity was shown by labelling with Alizarin Red S for bone nodules. This was
chosen for pragmatic reasons and further work should also stain for alkaline phosphatise.
4.3.4 Chondrogenesis
Further cells were taken for chondrocyte culture. 2x105 cells were also aliquoted into
centrifuge tubes and spun at 150G for 5 minutes. The resulting pellets were washed in PBS
three times then placed in chondrogenic media. This comprised: Glutamate 2 mmoFL,
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Dexamethasone 0.1 pmoFL, Ascorbic acid 50 pmol/L, Na-pyruvatel mmol/L, Proline 40
pmol/L, TGFP3IO ng/ml and ITS+ Premix (final concentrations: Bovine insulin, transferrin,
selenous acid 6.25pg/mL, Linoleic acid 5.3pg/mL, Bovine serum albumin 1.25mg/mL). The
chondrocyte pellets were sectioned on a cryostat and stained with Safranin Red O.
4.3.5Adipogenesis
The remaining cells were cultured in an adipogenic media. This comprised: complete media
with the addition of Dexamethasone pmol/L, IBMX 500 pmol/L, Insulin 1 pg/mL,
Indomethacin 100 pM.
Oil Red O was used to stain for adipocytes.
4.4 Results
The gap tissue proved to be quite delicate and very small samples were obtained (1 -
3.3mm3 approximately. Here samples were used to refine the harvesting and culture
method as shown in table one. Five animals were used for the experiment as shown in
table 2. Only 3 samples provided enough cells for final analysis (60%).
Table 5 Samples used to establish optimal extraction and plating technique as
recorded in the methods section.
Number of samples Outcome
n=l Handling error leading to loss of cell in
the extraction process (collagenase used)
n=2 Trypsin time thought to have been too
long with poor adherence of cells to flask
and cell loss at first media change
Table 6 Samples used in final cell culture
Number of samples Outcome
n=l 90% confluence not achieve from initial
culture
n=l Failed to achieve confluence after first
passage
n=3 Confluence achieved after first passage
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and sufficient cells for final analyses (10
000/well)
Osteogenic potential
The alizarin showed a degree of calcification in the control media but not in a nodular
pattern. Staining of the adipogenic wells with alizarin was negative. In the osteogenic wells,
the nodule pattern and the positive staining with alizarin were compatible with there being
osteoblastic activity present.
Chondrogenie potential
The pellets stained positively for Safranin Red O, supporting the presence of chondrogenic
activity.
Adipogenic potential






The results presented here support the assertion that gap tissue from the site of an atrophic
126fracture non-union is not inert. The vascularity, metabolic activity and cell turnover of
human atrophic non-union tissue and that of the gap tissue in the model used for this study
has already been demonstrated 149. The work presented here has shown that the tissue
contains cells that retain the in vitro capacity for osteogenic activity. These findings provide a
rationale basis for interventions that could potentially drive the intrinsic material in an
osteoblastic direction to achieve union. The work also showed that the tissue was relatively
delicate as was also observed by Boyan et al'5'. Once the procedure had been refined only
four of the samples had sufficient cell division to allow a passage and only 60% had
sufficient growth for the final analyses.
A lag in revascularisation of the non-union site relative to normal fracture healing l25,127'149
has been noted. The other markers ofmetabolic activity have also shown temporal lags 126 153.
It has been hypothesized that the factors not being present at the appropriate time
contributes to the formation of the non-union126 , however the lag in appearance of the
vascularity and metabolic activity could equally be argued to be a result of the non-union
rather than the cause of it. Seebach et al 129 quantified the colony-forming units (cfu's) of
mesenchymal cells in multi-trauma patients, those with a single fracture and those with a
fracture non-union. Interestingly they showed the highest numbers in multiply injured
patients. These result from high energy trauma and have the highest rates of fractures going
on to non-unions. They also demonstrated gender differences. These data suggest that the
reasons for failure of osseous healing are more complex than lack of stem cell capacity or
lack of growth factor stimulation. The work by Seebach et al suggests that in high energy
trauma the systemic biological capacity for healing is higher than uninjured volunteers and
therefore further stimulation in the acute phase may not lead to a further increase in activity
and subsequent decrease in non union rate.
Osteogenic potential has been demonstrated in the gap tissue from a canine mode161. This
model used a 3mm defect created in the midshaft of the radius with an oscillating saw. This
reliably fails to heal and although a fibrous defect is created, the magnitude of the defect
mean it is less clinically analogous as this gap size would not be accepted in clinical practice.
The work presented here confirmed that a similar potential was present in the tissue from a
validated, more clinically relevant model of an established atrophic non union. Work
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published after this research undertaken has subsequently also demonstrated that cells
retaining multipotential mesenchymal properties can be isolated from human hypertrophic
non-union tissue 128'152. This would suggest that the same potential is present in human
hypertrophic non-unions. It would be interesting to compare tissue from the non-union
models to that of humans with regard to osteoblastic potential. This was beyond the scope of
the current study.
The osteoblastic potential was explored by Lawton et al137438 who suggested that
osteoblasts associated with a non-union showed atypical phenotypes. Hofmann et al 132 have
examined this further and found that these osteoblasts also have reduced viability and
replication potential. In addition to altered biology there is also evidence that the reservoir of
121 123 129osteoblastic cells is depleted in chronic fracture non unions
Altering fracture mechanics by augmentation or substitution of the fixation method can lead
to successful healing of fracture non union without exposing or intervening at the non-union
site16. This suggests that with additional control of the forces across the tissue, the biological
drive returns to ossification. It raises the question as to whether driving the biology alone
could be sufficient to increase the intrinsic stability of the non-union site and provide
conditions conducive to ossification.
This work suggests that there is tissue within this complex biological system that can
demonstrate pluripotentiality and cells that can proliferate given the correct conditions.
Clinical experience suggests that the tissue can remain adaptive in keeping with the
experimental findings, provided that the appropriate mechanical environment is present.
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Chapter 5: AdBMP2 and TP508 treatment of atrophic fracture non-union
5.1 Introduction
AdBMP2 (i.e. the BMP2 gene construct with an adenoviral insertion vector) has been shown
to be effective in achieving osseous bridging of critically sized defects in a rat and rabbit
model99'l01'104. TP508 has shown similar potential in a mouse and rabbit models76,80'89. This
study evaluated these orthobiological agents in a rat model of established 'atrophic' non¬
union. The latter model is more analogous to the currently used definition of an 'atrophic'
90 •
non-union . The principle outcome measures for this study were radiographic and
mechanically confirmed osseous union. The secondary endpoints were histological analysis
for vascularity and osteoblastic activity. The hypothesis was that biological potential in
fracture non-union tissue can be stimulated leading to osseous union by closed percutaneous
injection of induction factors.
5.2 Method
The rat model of atrophic fracture non union was created as already described. The 8 week
radiographs were performed in the standardised fashion. With the animal still anaesthetised
and the leg secure in the jig, the non union site was cleansed with Betadine antiseptic
solution. All injections were carried out using a 0.3ml syringe and 26G needle. The needle
was introduced through the skin obliquely from the lateral side with the bevel facing the
proximal bone end. The tip was advanced until contact was made with the bone then
swivelled through 180° so that the solution was injected into the osteotomy gap. The test
suspension was injected directly into the fibrous tissue at the non union site. The area was
then cleaned again and the animal wrapped and recovered in its cage.
5.2.1 Adenoviral construct andAmplification
Aliquots of replication-defective. El - and E3-gene deleted adenoviral vector encoding for
BMP2 were kindly supplied by Professor. CH Evans, Center for Molecular Orthopaedics,
Harvard Medical School. This stock virus was amplified on HEK 293 cells. The adenoviral
particles were extracted and purified using the BD Adeno-X™ purification kit. The infectious
titre of the purified viral solution was calculated using the BD Adeno-X™ Rapid Titre Kit
then stored at -80°C. On the day of injection the AdBMP-2 was thawed and re-suspended as
aliquots of lxl 07 and lxlO9 in lOpl PBS. This was kept on ice pending injection. The doses
used were inclusive of the range of doses in previous work99'101.
6.2.2 Preparation of thrombinpeptide solution/suspension
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TP508 peptide was supplied by Orthologic. It was supplied in powder form for use as a
solution and as a microsphere scaffold loaded form for use as a suspension. The latter
provided a controlled release that has been shown to be more favourable when the peptide is
used in bone healing 81. The solution and the suspensions were prepared using the
manufacturer's guidelines and the doses used were the same as have been published in
previous work77'81-. The solution /suspension was prepared under sterile conditions using
sterile phosphate buffered saline (PBS) so that the experimental concentration was in 10pL.
5.2.3 Groups
Each group consisted of 5 animals.
Adenoviral groups
Group I AdBMP2 at lxlO5
Group II AdBMP2 at lx 107
Group III AdBMP2 at lxlO9
Group IV AdLacZ at lxlCP
Group V AdLacZ at 1 x 107





Microspheres Group I Low dose
Group II High Dose
Control No intervention
5.2.4 Radiographic assessment
Radiographs were taken at time point zero (8 weeks following the initial surgery to create the
non-union), the time of the treatment injection. If there was any suggestion of osseous
activity at the non-union site the animal was excluded from the trial. Further radiographs
were then performed at the 2 week, 4 week and final 8 week time points to assess for bone
formation. Radiographs were performed by fixing the frame in a specially designed jig. This
was placed on the cassette containing the film at a fixed distance of 50cm from the source.
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An exposure time of 0.5mS and a dose of 50mKVA were used. An anterior-posterior (AP)
and oblique (O) (45°) were taken for each animal.
Radiographs were assessed using a visual analogue scale. All radiographs were graded
independently by two experienced orthopaedic surgeons. The scale used is outlined in Table
7 below.
Figure 8 Samples of the Xrays at each of the time points showing that the non-union site
failed to ossify.











Table 7 Radiographic scoring system used to grade the radiographic evidence of osseous
activity in the non-union site.
Radiographic findings Score
No identifiable activity 0
Calcification in fracture gap 1
One cortex bridged 2
Two cortices bridged 3
Three cortices bridged 4
Four cortices bridged 5
Complete healing 6
5.2.5 Harvesting ofnon-union
At the eight week time point all animals were sacrificed using a chamber with a rising
concentration of carbon dioxide in accordance with the Home Office guidelines. Final
radiographs were obtained immediately. Using aseptic technique, in a sterile field, the skin
overlying the non-union site was then excised. The tibia proximal and distal to the gap was
exposed and osteotomised using the 0.8mm burr leaving a 2mm cuff of bone on each side of
the gap. The construct was freed from the surrounding muscle talking care not to disturb the
site of the non-union. It was soaked in 5% polyvinyl alcohol (PVA) for 5 minutes then placed
in a freezing bath of hexane at -80°C for a further 5 minutes. The sample was then stored at -
80°C until sectioning. 7pm sections were taken through the non-decalcified samples using a
cryostat. They were captured on a glass slide and fixed in 4% paraformaldehyde (PFA) for 10
minutes followed by three five minute washes with PBS. The fixed sections were stored at
4°C.
5.2.6 Histology
Analysis was performed by Dr. Cristina Huber, Musculoskeletal Laboratory, Edinburgh using
von Kossa staining to indicate osteoblastic activity and immunohistochemical staining using
an antibody against von Willebrand factor to determine vascularity. The area of positive
staining for von Kossa and the vessel count per high powered field across 5 fields were
measured for each sample.
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5.3 Results
All animals continued to display quadripedal gait and bipedal stance using the affected limb
throughout the study period.
Xray
No difference was found between the control and treatment groups radiographically. All
scored zero on the scale outlined above.
There were no differences between the different concentrations of AdBMP2. There was also
no difference between the different concentrations and preparations of TP508.
Mechanical testing
Mechanical testing was performed in an earlier series to show that where there was no
radiographic indication of healing (i.e a score of 0 on the scale above) there was less than
0.1N resistance to a bending force applied in a 3-point manner, i.e. there was no intrinsic
mechanical stability and the sample deflected under its own weight.
Therefore, neither AdBMP2 or TP508 were effective in producing clinical/mechanical union
or in creating radiographically apparent osseous activity.
Histology
(Sections courtesy of Christine Huber)
Figure 9 Von Kossa staining of the TP508 groups
This showed some evidence of bone nodule formation in the high and low dose TP508
groups (a and b) but not in controls(c). There was however no radiographic evidence of
union in any group. Bar = 100pm x 200 magnification
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a. high dose
In the TP508 high and low dose microsphere groups, there were increases of 43.9% and 9.9%
in bone formation relative to the control group. There was also a statistically significant
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difference in vessel density between the TP508 groups and controls but not between high and
low dose groups.
5.4 Discussion
Both TP508 and AdBMP2 have been shown to be effective in stimulating ossification of
critically-sized defects, fractures and the anlage produced by distraction osteogenesis in small
animal models. The model in this study is a non-critically-sized gap model of'atrophic' non¬
union and is more analogous to the current clinic definition20. The main outcome in this study
was radiographic evidence of osseous activity or bridging bone. A radiographic assessment
along with a clinical assessment (mechanical, functional, pain) is how union is determined in
clinical practice. In contrast to the previous reports in rat99'101 and rabbit models104, there was
no evidence of clinically significant osseous activity in fracture gap in this clinically
analogous model.
The methodology used the same preparation protocols and injection techniques that have
been used in the other models 11' * '101. Betz et al 101 demonstrated that the viral product
was delivered into the non-union site and produced sustained quantities of BMP2 locally with
negligible systemic effect. With regard to TP508, previous work has also shown that the
preparation can be effectively delivered to the non union site by this method 77"81.
The work presented here represents a further step from the gap models where both AdBMP2
and TP508 have been shown to be effective 76-77>79-81'89'99' 101> 104> '54-155 jn t^e cijnjcai
situation, a non-union is often the result of both biological and mechanically unfavourable
conditions. The model used here is representative of this situation.
In order to be useful in the treatment of fracture non-union, ideally the peptides needed to
demonstrate efficacy in models of the established non-union situation. The test substrate was
introduced into the gap tissue 8 weeks from the initial surgery. In almost all of the previous
animal studies showing efficacy it was injected in very early in the post operative period.
This may represent a more biologically favourable environment than the model used in this
study. Clinically recombinant BMP2 has been used in this manner. However, the treatment is
expensive and further evidence of its efficacy and cost effectiveness would be of value. %.
The histological analysis of the TP508 microsphere samples demonstrated increased vascular
and ossific activity. However, whilst these results are encouraging and were statistically
significant, they did not represent a clinically significant improvement as indicated by an
increase in union rate. At the time of this study, Orthologic were considering marketing
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TP508 for the treatment of non-union. It had already been used in clinical trials in distal
radial fractures 88. Based partly on the preliminary results of this work, the marketing strategy
has now been directed away from its use in the non-union situation.
The reasons for failure of healing in the current study are not clear from the available data.
Although the techniques used were a replication of those from other successful studies,
further work is required to demonstrate that the appropriate quantities ofBMP2 and TP508
were delivered at the non-union site. Only then can the assumption be accepted that it is the
biological environment that is the main contributory factor in the failure of union.
There are problems inherent in the long term treatment of fractures with external fixation
devices in both patients and animal models. Wire loosening and breakage and infection leads
to loss of mechanical integrity of the construct. The animals were monitored closely in the 8
weeks leading up to the intervention point. Radiographs were undertaken at 4 weeks. Overall,
5% showed signs of osseous activity and went on to heal by the 8 week mark. None of these
animals were included in the study groups but this suggests that the construct was robust and
maintained mechanical stability. No animals that had failed to show radiographic evidence of
healing at 4 weeks went on to heal. In rats, loss of mechanical integrity of a limb leads the
animal to exclude it in gait or weightbearing because of pain. All animals were checked on a
daily basis by the investigator and also by the facility staff. All continued to exhibit
quadripedal gait and bipedal standing. Where there were any concerns a home office
veterinary surgeon was contacted and the animal euthanized. None of these animals were
included in the final experimental groups. These data suggest that there was no major issue
with mechanical stability of the construct.
Infection is one of the major causes of fracture non-union. If infected, there are signs of either
suppuration around the pinsites or failure of the animal to gain weight. In addition to the
animal checks outlined above, there were several groups used in a different experiments
where the non union material was harvested at 8 weeks and used for cell culture. None of
these cultures showed any evidence of infection. In the experimental groups therefore, no
evidence could be found of infection contributing to failure of the interventions.
The model of fracture non-union used in this study is analogous in many respects to the
clinical situation. However, it is a hostile environment in terms of osseous healing, probably
much more so than many of the gap models employed to evaluate novel approaches to the
treatment of non-union. This may indicate that percutaneous injection as a treatment of non-
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union clinically may be more difficult than suggested by the work using small animal gap
models. Further work is needed before this can be trialled as a clinical solution.
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Chapter 6: Discussion
6.1 Evaluation the biological potential offracture non-union gap tissue
This thesis has presented preliminary work aimed at characterising the biological potential
and character of fracture non-union gap tissue. It began with an appraisal of the current
literature on the classification and treatment of fracture non-union. It then detailed work that
investigated activity in genes associated with osteoblastic and osteoclastic processes in
human non-union tissue. Much that is understood about fractures and fracture non-union
comes from animal models. In the subsequent chapters work was presented that used a rat
model of fracture non-union to firstly, examine the osteoblastic potential of the gap tissue and
evaluate percutaneously injected a viral vector (AdBMP2) and recombinant protein (TP508)
as a method ofdriving the biology of the gap tissue to treat the non-union.
6.2 Definition
Defining when a fracture has healed remains problematic. Corrales et al9 could not find a
consensus on the definition of fracture healing when they reviewed the publications from the
main orthopaedic journals. Bhandari et al'° published similar findings when they surveyed
the international orthopaedic community. This makes definition of fracture non-union even
more problematic. The FDA definition13 is widely quoted and provides a standard but that of
Frolke14 is pragmatic and aligned to clinical practice. It is the latter definition that a non¬
union was 'a disturbance of normal healing with the expectation that no consolidation will be
achieved without focused and accurate treatment' that was used in this work.
6.3 Classification and treatment
The classification of fracture non-union still relies on the system proposed by Weber and
Cech in 197616. Others that have been published17"19 but are adaptations or derivations of this
system. Is a classification proposed over 35 years ago still relevant? Examination of then-
work would suggest that most of their proposals are supported by recent vascular studies125-
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, cell biology ' , growth factor and RNA analyses . In addition, despite their cautions,
the biological potential of the non-union sites continues to be mis-classified20 and
underestimated21-73. The use of bone graft, most often autologous remains the standard in
treatment of fracture non-union. It still has a high associated morbidity64 and there is again a
lack of clarity in the literature regarding the exact indications and timing of intervention. The
work ofBlick et al105 remains the most widely quoted. Techniques and principles,
particularly regarding soft tissue cover for severe fractures have evolved considerably109 but
from their heterogenous dataset they set the standard of two weeks following soft tissue cover
56
for autologous bone grafting that remains the practice today. Weber and Cech16 reserved
grafting mainly for large bone defects, particularly following infection and suggested that
most often improving the stability is sufficient. Current indications are not clear and opinion
therefore still relies on historical series. There have been no randomised controlled trials
comparing grafting (including timings) and better mechanical stability alone. Instead, if
anything a more aggressive approach that utilises revised fixation and orthobiologics21,73
(usually bone morphogenetic protein 7 (BMP7)) is being promoted by several groups. Other
modalities of treatment are available but good evidence of their efficacy is lacking110'118"119'
122,156-159
6.4 Characterising the gap tissue in human fracture non-union
The gap tissue at the site of a fracture non-union is still considered to be either inert or
ni I/- 198
inhibitory ' . This view has continually been challenged and Iwakura et al were able
to isolate cells with osteoblastic potential from hypertrophic non-union tissue. Brownlow and
coworkers125"127 also suggested good biological potential in their work on animal models and
human tissue. In the work presented in this thesis, a feasibility study was undertaken to
determine if it were possible to quantify activity in the genes associated with bone healing
processes from small samples of non-union tissue such that it could be related to the
histological appearance and clinical behaviour. The hypothesis that there would be sufficient
cells in sampled non-union tissue to profile activity in the genes related to fracture healing
was supported. Uniformly only very small amounts of nucleotide was obtained from the
sample. The tissues showed marked heterogeneity and when two samples from the same non¬
union were processed separately these also showed marked differences. The study did show
that it was possible to profile the gene activity for osteoblastic and osteoclastic processes and
supported the hypothesis. This was a feasibility study primarily due to time and financial
constraints so further analyses was not possible. The implications are that the scintigraphy
activity used by Weber and Cech16 could be quantified as gene activity. The sample sizes
were similar to those obtained for tissue biopsies of bone tumours meaning that it has
potential clinical utility in determining healing potential and directing specific treatment
modalities.
6.5Matrix characteristics andfracture non-union
The histology presented here is illustrative of the tissue appearance. It was processed from
tissue directly adjacent to that used for the RNA analysis and is therefore likely to share
characteristics.
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The matrix characteristics of the non-union tissue have not been given much consideration in
the published literature but probably warrant further investigation. Ashhurst 139' 160observed
that osteoblastic replacement of the cartilage anlage was preceded by osteoclasts. Wassen et
al'6' also commented on this and showed that there were differences in the collagen structure
of the initial callus and the final collagen pattern of the remodelled bone. They demonstrated
that the initial collagen, although Type I was subtly different to that of bone and promoted
crystallisation between rather than within the helices. This fits with the descriptions by Wen
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et al and Lawton et al ' . The Wassen group then showed that the whole structure
including the collagen I structure was then remodelled to achieve final healing. It is therefore
feasible that non-union represents an arrest in the replacement of this initial matrix and is by
definition therefore heterogenous the process stops or slows at different stages in different
parts of the tissue and in different fractures. The matrix constituents are biologically active
and binding sites differ depending on conditions. Surprisingly, there is virtually no work
looking at the matrix morphology ofnon-union tissue and the osteoclast processes. In
particular, further work has been proposed to determine if it is a lack of osteoclastic (brown
on the TRAP staining here) binding moieties in the non-ossified collagenous matrix (blue on
the Masson-Trichrome stains) prevents the active cellular areas from linking. If this were the
case, then driving the biology alone is likely to fail unless it is preceded by a process that
disrupts that block.
6.6 Animal models in fracture non-union
This work has again questioned the use of models to look at fracture non-union. Many gap
76 77 79 80 88 89 99models suggested that the biological agents used here had excellent potential
101,104,154-153 kut macje no ciinicaiiy significant impact on the model used here, one that is
a closer representation of the clinically presenting non-union. Even this model has
limitations and although models remain useful in refining research questions, they do not
necessarily provide data that is open to direct clinical translation. Attempts to do so have led
to relatively disappointing translational results75' "°.
Further work is needed in properly characterising the non-union tissue itself, tissue that has
n? ii7
too often been ignored in experimental design ' . In addition, particularly if models are
to be used, the gap tissue from these needs to be compared to that from humans to validate
126 128 151the similarities and differences. The data presented here and in other work " ' suggest
that biological intervention may still have a role but the data from the animal model in this
thesis emphasises that this needs to be better directed if translational strategies are to be
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effective and reliable. This work demonstrated the feasibility ofprofiling the mesenchymal
and osteoclastic activity of the gap tissue using very small samples. Work is ongoing using a
large patient series to determine if the gene activities can be used to indicate healing potential
along the lines of the trends demonstrated here. Fracture non-unions in patients are
heterogenous at multiple levels and this also needs to be accounted for in experimental
designs. The metabolic profile may be a useful tool in this regard.
6.7 Orthobiologics andfracture non-union
Orthobiological agents have shown potential particularly in gap models of non-union. This
work used the same techniques and constructs in a rat model that has been validated and is
analogous to the clinical situation. These agents were not sufficient when used in isolation in
this model. The hypothesis for this work was that stimulation of the inherent potential of
fracture non-union tissue with closed percutaneous injection of biologically active agents can
lead to osseous union.
This work was unable to demonstrate evidence to support this hypothesis. The strength of the
design is that it replicated the techniques and used the same constructs that have been
successful in other models. The major difference is that it was delivered at a much later time
point to replicate the clinical picture. The weaknesses are that the tissue has not been
examined for markers of successful delivery nor the effective dose quantified. This needs to
be addressed in future work before it can be said with certainty that the lack of effect is due to
the chronic characteristics of the non-union rather than a methodological problem. It appears
that stimulation of the tissue with orthobiological agents alone is insufficient. The
recombinant protein technology, particularly when coupled with viral vectors as a delivery
mechanism, appear to be very potent tools from laboratory data. However, until the biology
of clinically presenting non-unions is better defined their translational impact may remain
muted.
6.8 Further work
Fracture non-union presents many problems in terms of research as well as clinically. There
is no real consensus with regard to definition and classification. Although the Weber and
Cech system remains the most used it is widely misquoted making interpretation of results
problematic. On a clinical level parameters need to be agreed with regard to reporting if data
are to be appropriately compared. Only then can treatments from revision fixations and bone
grafting through to the use of recombinant proteins be rationalised.
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127 132Non-union tissue has often been compared to healing or cancellous bone ' . The work of
Weber and Cech16, although over 35 years old remains very relevant particularly since they
demonstrated that mechanical stability alone would lead to healing with most non-unions.
One question raised by this thesis is: how do the gene profile and the histological appearance
of the tissue change as it transforms from steady state non-union tissue to reactive tissue to
bone? A second question is: can the changes induced by alteration of the forces be
reproduced using a biological stimulus? Finally, the preliminary examination of the
histology, in combination with the Ashhurst139"160 and Wassen161 work question the role of
the hitherto ignored osteoclasts. Frost162 placed them at the front of the basic multicellular
unit and they precede ossification. Therefore their histomorphometric distribution may be a
crucial key to understanding why biological agents alone may be insufficient to achieve
healing. Further work is therefore needed to elucidate the distribution of osteoclasts in non¬
union tissue and their relationship to the non-calcified matrix.
6.9 Concluding remarks
The hypothesis for the thesis was: there is quantifiable biological potential in fracture non¬
union tissue that can be stimulated leading to osseous union by closed percutaneous injection
of induction factors. The work did not produce evidence to support that the biological
potential of the non-union tissue can be stimulated to lead to healing by the percutaneous
means described. It did however demonstrate the feasibility of quantifying the biological
potential of the non-union gap tissue. It also demonstrated that it would be possible to
correlate this to the histological appearance and clinical activity. These data have huge
potential both in research and clinically.
The tissue at the site of a fracture non-union retains quantifiable metabolic activity. Although
biological interventions have shown potential, they failed to produce healing in a more
challenging clinically analogous model. Much remains to be understood about non-union
tissue and the metabolic profiling demonstrated here is a potentially useful tool both
experimentally and clinically. Further work is needed to refine and validate the assays used
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